Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9217MR)

This product GTTS-WQ9217MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ9217MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7697MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GEXMab73
GTTS-WQ13302MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-06523435
GTTS-WQ12125MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MORAb-003
GTTS-WQ651MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 8c10
GTTS-WQ8270MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HM10560A
GTTS-WQ9719MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ11265MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI4736
GTTS-WQ10012MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA KRN-23
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW